http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102149698-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536
filingDate 2009-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96d2fb74e1052a5a3dd6393c8723212b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_159521585b358f55544fa5b716ce98e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c3d6468838b754990a99f5c8f909c4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b56432ece432f9f5b4bf400c463c2450
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b44742691fef9fe09b3b7ff376cb83db
publicationDate 2011-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102149698-A
titleOfInvention 5-substituted benzoxazines
abstract The present invention is concerned with 5-substituted benzoxazine derivatives of formula (I), wherein X, R1 and R2 are as described herein, as well as their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are 5-HT5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders or gastrointestinal disorders.
priorityDate 2008-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466622804
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467240398
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465554356
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467240397
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466663502
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467240394
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID455652967

Total number of triples: 38.